BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.71
$0.879.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 2.66M | 2.50M | 1.36M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 30.09M | 23.14M | 23.87M | ||
| Operating Income | -30.09M | -23.14M | -23.87M | ||
| Income Before Tax | -28.44M | -22.06M | -21.82M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -28.44M | -22.06M | -21.82M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -28.44M | -22.06M | -21.82M | ||
| EBIT | -30.09M | -23.14M | -23.87M | ||
| EBITDA | -30.02M | -23.08M | -23.82M | ||
| EPS Basic | -50.36 | -54.23 | -174.97 | ||
| Normalized Basic EPS | -31.48 | -33.89 | -109.35 | ||
| EPS Diluted | -50.36 | -54.23 | -174.97 | ||
| Normalized Diluted EPS | -31.48 | -33.89 | -109.35 | ||
| Average Basic Shares Outstanding | 564.60K | 406.70K | 124.70K | ||
| Average Diluted Shares Outstanding | 564.60K | 406.70K | 124.70K | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||